What is NeoIPC?
Establishing innovative approaches for optimal infection prevention of resistant bacteria in NICUs by integrating research, implementation science and surveillance in a sustainable global platform
NeoIPC is a large cluster randomised controlled trial in neonatal intensive care units, set up to investigate an infection prevention and control intervention in this setting. NeoIPC is establishing innovative approaches for optimal infection prevention of resistant bacteria in NICUs by integrating research, implementation science and surveillance.
Penta is the sponsor of the NeoIPC trial
Why is NeoIPC needed?
Identifying and investigating best practices and Infection Prevention and Control (IPC) interventions for dealing with resistant bacterial infections in neonatal intensive care is urgently needed. Currently, the management of resistant bacterial infection in this setting is fragmented, highly variable, poorly integrated and not supported by robust evidence.
What is NeoIPC’s goal?
NeoIPC is aiming to develop and implement an innovative approach towards the evaluation of infection prevention and control interventions, assess the effectiveness of interventions in a randomised controlled trial while also working towards the identification of a suitable implementation strategy. NeoIPC will also generate widely relevant and globally transferrable outputs to improve infection prevention and control in neonatal care.
NeoIPC is building a platform for research into IPC interventions in neonatal intensive care. The platform will establish standard IPC assessments for quality improvement and research and make use of innovative research methods to evaluate IPC interventions.
The NeoIPC Consortium to develop a European Neonatal Infection and Prevention Control Research and Implementation Network.
This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No. 825715.